Completed PHASE3 INTERVENTIONAL 3-arm NCT01458574

A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (OCTAVE)

A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis

Sponsor: Pfizer

Conditions Ulcerative Colitis

Interventions CP-690,550 CP690,550 Placebo

Updated 8 times since 2017 Last updated: Apr 7, 2017 Started: Jul 20, 2012 Primary completion: May 27, 2016 Completion: May 27, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Ulcerative Colitis, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Jul 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus C, Denmark , Alpharetta, United States , Amiens, France , Amsterdam, Netherlands , Ann Arbor, United States , Antwerp, Belgium , Atlanta, United States , Auckland, New Zealand , Austin, United States and 172 more locations